Charifson, Paul S.
Harvard Medical School,
United States
2025 Rank: 205229
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Chemistry
SubField 1:
Medicinal & Biomolecular Chemistry
SubField 2:
Biochemistry & Molecular Biology
Rank in SubField 1: 824 out of 112089 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 205229 | 232359 |
| Total Cites | 5007 | 5175 |
| H-index | 32 | 33 |
| Hm-index | 9 | 9 |
| Number of Single Authored Papers | 1 | 1 |
| Total Cites to Single Authored Papers | 27 | 27 |
| Number of Single+First Authored Papers | 13 | 13 |
| Total Cites to Single+First Authored Papers | 1339 | 1374 |
| Number of Single+First+Last Authored Papers | 35 | 35 |
| Total Cites to Single+First+Last Authored Papers | 3502 | 3584 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 4200 | 4301 |
| Ratio of Total Citations to Distinct Citing Papers | 1.19 | 1.20 |
| Self-Citation Percentage |
3.25%
|
|
Charifson, Paul S.
Vertex Pharmaceuticals, Inc.,
United States
2024 Rank: 193431
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Chemistry
SubField 1:
Medicinal & Biomolecular Chemistry
SubField 2:
Biochemistry & Molecular Biology
Rank in SubField 1: 755 out of 105998 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 193431 | 219351 |
| Total Cites | 4800 | 4967 |
| H-index | 32 | 33 |
| Hm-index | 9 | 9 |
| Number of Single Authored Papers | 1 | 1 |
| Total Cites to Single Authored Papers | 27 | 27 |
| Number of Single+First Authored Papers | 13 | 13 |
| Total Cites to Single+First Authored Papers | 1284 | 1319 |
| Number of Single+First+Last Authored Papers | 35 | 35 |
| Total Cites to Single+First+Last Authored Papers | 3352 | 3433 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 4010 | 4110 |
| Ratio of Total Citations to Distinct Citing Papers | 1.20 | 1.21 |
| Self-Citation Percentage |
3.36%
|
|
Charifson, Paul S.
Vertex Pharmaceuticals, Inc.,
United States
2023 Rank: 182479
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Chemistry
SubField 1:
Medicinal & Biomolecular Chemistry
SubField 2:
Biochemistry & Molecular Biology
Rank in SubField 1: 698 out of 99369 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 182479 | 207137 |
| Total Cites | 4577 | 4742 |
| H-index | 32 | 33 |
| Hm-index | 9 | 9 |
| Number of Single Authored Papers | 1 | 1 |
| Total Cites to Single Authored Papers | 27 | 27 |
| Number of Single+First Authored Papers | 13 | 13 |
| Total Cites to Single+First Authored Papers | 1236 | 1271 |
| Number of Single+First+Last Authored Papers | 35 | 35 |
| Total Cites to Single+First+Last Authored Papers | 3193 | 3272 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 3814 | 3912 |
| Ratio of Total Citations to Distinct Citing Papers | 1.20 | 1.21 |
| Self-Citation Percentage |
3.48%
|
|
Charifson, Paul S.
Vertex Pharmaceuticals, Inc.,
United States
2022 Rank: 170604
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Chemistry
SubField 1:
Medicinal & Biomolecular Chemistry
SubField 2:
Biochemistry & Molecular Biology
Rank in SubField 1: 644 out of 94672 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 170604 | 194819 |
| Total Cites | 4341 | 4508 |
| H-index | 31 | 32 |
| Hm-index | 9 | 9 |
| Number of Single Authored Papers | 1 | 1 |
| Total Cites to Single Authored Papers | 27 | 27 |
| Number of Single+First Authored Papers | 13 | 13 |
| Total Cites to Single+First Authored Papers | 1178 | 1213 |
| Number of Single+First+Last Authored Papers | 35 | 35 |
| Total Cites to Single+First+Last Authored Papers | 3041 | 3122 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 3610 | 3710 |
| Ratio of Total Citations to Distinct Citing Papers | 1.20 | 1.22 |
| Self-Citation Percentage |
3.70%
|
|
Charifson, Paul S.
Vertex Pharmaceuticals, Inc.,
United States
2021 Rank: 163377
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Chemistry
SubField 1:
Medicinal & Biomolecular Chemistry
SubField 2:
Microbiology
Rank in SubField 1: 625 out of 88725 Researchers
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 163377 | 186655 |
| Total Cites | 4204 | 4365 |
| H-index | 31 | 32 |
| Hm-index | 9 | 9 |
| Number of Single Authored Papers | 1 | 1 |
| Total Cites to Single Authored Papers | 27 | 27 |
| Number of Single+First Authored Papers | 13 | 13 |
| Total Cites to Single+First Authored Papers | 1139 | 1174 |
| Number of Single+First+Last Authored Papers | 35 | 35 |
| Total Cites to Single+First+Last Authored Papers | 2946 | 3025 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 3505 | 3600 |
| Ratio of Total Citations to Distinct Citing Papers | 1.20 | 1.21 |
| Self-Citation Percentage |
3.69%
|
|
Charifson, Paul S.
Vertex Pharmaceuticals, Inc.,
United States
2020 Rank: 149716
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Chemistry
SubField 1:
Medicinal & Biomolecular Chemistry
SubField 2:
Microbiology
Rank in SubField 1: 728 out of 80622 Researchers
Data For The Year: 2020
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 149716 | 171316 |
| Total Cites | 3906 | 4066 |
| H-index | 31 | 32 |
| Hm-index | 9 | 9 |
| Number of Single Authored Papers | 1 | 1 |
| Total Cites to Single Authored Papers | 27 | 27 |
| Number of Single+First Authored Papers | 13 | 13 |
| Total Cites to Single+First Authored Papers | 1082 | 1117 |
| Number of Single+First+Last Authored Papers | 35 | 35 |
| Total Cites to Single+First+Last Authored Papers | 2749 | 2827 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 3248 | 3342 |
| Ratio of Total Citations to Distinct Citing Papers | 1.20 | 1.22 |
| Self-Citation Percentage |
3.94%
|
|